SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+10.37%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$2.43B
AUM Growth
+$2.43B
(+4.8%)
Cap. Flow
+$27.8M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
44.17%
Holding
71
New
12
Increased
26
Reduced
26
Closed
7
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$43.8M |
| 2 |
AEGR
Aegerion Pharmaceuticals, Inc.
AEGR
|
$43.1M |
| 3 |
Thermo Fisher Scientific
TMO
|
$32.3M |
| 4 |
FRX
FOREST LABORATORIES INC
FRX
|
$24.9M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$24.6M |
Top Sells
| 1 |
Perrigo
PRGO
|
$50.2M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
$24.8M |
| 3 |
Merck
MRK
|
$24.2M |
| 4 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$22.7M |
| 5 |
CELG
Celgene Corp
CELG
|
$19.6M |
Sector Composition
| 1 | Healthcare | 92.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Novo Nordisk
NVO
$252B
| $6.24M | 0.26% |
136,610
+116,484
| +579% | +$1.64M |
|
52
Inogen
INGN
$213M
| $4.68M | 0.19% |
+283,410
| New | +$4.68M |
|
53
Accuray
ARAY
$165M
| $4.64M | 0.19% |
483,739
-384,647
| -44% | -$3.69M |
|
54
DexCom
DXCM
$30.9B
| $2.95M | 0.12% |
71,346
-88,871
| -55% | -$3.68M |
|
55
Novartis
NVS
$248B
| $2.65M | 0.11% |
31,200
+19,100
| +158% | +$1.62M |
|
56
Carisma Therapeutics
CARM
$15.5M
| $812K | 0.03% |
+50,000
| New | +$812K |
|
|
ANTH
57
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $742K | 0.03% |
+221,462
| New | +$742K |
|
|
CBIO
58
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $728K | 0.03% |
+44,587
| New | +$728K |
|
59
Tandem Diabetes Care
TNDM
$834M
| $665K | 0.03% |
30,100
+10,100
| +51% | +$223K |
|
|
FPRX
60
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $636K | 0.03% |
+32,372
| New | +$636K |
|
|
APEN
61
DELISTED
Apollo Endosurgery, Inc.
APEN
| $601K | 0.02% |
+126,464
| New | +$601K |
|
62
Arbutus Biopharma
ABUS
$753M
| $591K | 0.02% |
+27,500
| New | +$591K |
|
63
Neurogene
NGNE
$284M
| $382K | 0.02% |
+30,000
| New | +$382K |
|
|
WX
64
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $247K | 0.01% |
6,690
+690
| +12% | +$25.5K |
|
|
MDVN
65
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-388,760
| Closed | -$24.8M |
|
|
PCYC
66
DELISTED
PHARMACYCLICS INC
PCYC
| – | – |
-168,425
| Closed | -$17.8M |
|
|
RLYP
67
DELISTED
RELYPSA INC COM
RLYP
| – | – |
-50,000
| Closed | -$1.25M |
|
|
XLRN
68
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – |
-9,827
| Closed | -$389K |
|
|
69
Perrigo
PRGO
$3.21B
| – | – |
-327,268
| Closed | -$50.2M |
|
70
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-35,000
| Closed | -$802K |
|
71
Hologic
HOLX
$14.7B
| – | – |
-239,485
| Closed | -$5.35M |
|